NASDAQ:CERE Cerevel Therapeutics (CERE) Stock Price, News & Analysis $44.96 +0.33 (+0.74%) (As of 08/1/2024) Add Compare Share Share Today's Range$44.96▼$44.9950-Day Range$38.96▼$44.9652-Week Range$19.59▼$44.99Volume15.10 million shsAverage Volume1.71 million shsMarket Capitalization$8.19 billionP/E RatioN/ADividend YieldN/APrice Target$44.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get Cerevel Therapeutics alerts: Email Address Cerevel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.13 Rating ScoreUpside/Downside1.9% Downside$44.13 Price TargetShort InterestHealthy6.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$1.03 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.59) to ($2.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.25 out of 5 starsMedical Sector909th out of 924 stocksPharmaceutical Preparations Industry423rd out of 426 stocks 1.1 Analyst's Opinion Consensus RatingCerevel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageCerevel Therapeutics has received no research coverage in the past 90 days.Read more about Cerevel Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.83% of the float of Cerevel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCerevel Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cerevel Therapeutics has recently decreased by 9.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCerevel Therapeutics does not currently pay a dividend.Dividend GrowthCerevel Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERE. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added Cerevel Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerevel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,029,500.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Cerevel Therapeutics is held by insiders.Percentage Held by Institutions87.73% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cerevel Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.59) to ($2.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerevel Therapeutics is -16.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerevel Therapeutics is -16.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerevel Therapeutics has a P/B Ratio of 12.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe Strange Disappearance of MILLIONS of American JobsA former hedge fund manager who bought Apple at a split-adjusted 35 cents and Amazon at $2.40 (split adjusted) just went issued a major warning.You can watch our interview, here, free of charge. About Cerevel Therapeutics Stock (NASDAQ:CERE)Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.Read More CERE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERE Stock News HeadlinesAugust 14, 2024 | msn.comAnalyst revises AbbieVie stock price target on drug-sale estimatesAugust 6, 2024 | ca.finance.yahoo.comABBV Sep 2024 200.000 callAugust 22, 2024 | Stansberry Research (Ad)Famous Stock Market Bull Issues Rare “Collapse” WarningTilson says we're in the midst of a collapse – unlike any we've seen since 2008. As you'll see, it all centers around the tech sector. And the epicenter – it turns out – is Apple.August 5, 2024 | ca.finance.yahoo.comABBV Aug 2024 245.000 callAugust 4, 2024 | uk.finance.yahoo.comABBV Aug 2024 187.500 putAugust 3, 2024 | uk.finance.yahoo.comABBV Aug 2024 160.000 callAugust 1, 2024 | markets.businessinsider.comAbbVie Completes Acquisition Of Cerevel; Reaffirms Full-year Adj. EPS Guidance RangeAugust 1, 2024 | prnewswire.comAbbVie Completes Acquisition of Cerevel TherapeuticsAugust 22, 2024 | Stansberry Research (Ad)Famous Stock Market Bull Issues Rare “Collapse” WarningTilson says we're in the midst of a collapse – unlike any we've seen since 2008. As you'll see, it all centers around the tech sector. And the epicenter – it turns out – is Apple.August 1, 2024 | finance.yahoo.comCerevel Therapeutics Holdings Inc (673.MU)July 26, 2024 | ca.finance.yahoo.comIMGN Dec 2025 10.000 putJuly 26, 2024 | bizjournals.comAfter FTC involvement, here’s when AbbVie-Cerevel deal could closeJuly 25, 2024 | benzinga.comCheck Out What Whales Are Doing With CEREJuly 25, 2024 | msn.comCerevel ticks higher as AbbVie says it expects deal to close soonJuly 22, 2024 | msn.comCerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVieJuly 20, 2024 | msn.comWeight Loss Pills Intensify Obesity Drug Race—But Here’s Why Experts Say Injections Aren’t Going AnywhereJune 27, 2024 | insidermonkey.comWhy Is Cerevel Therapeutics Holdings, Inc. (CERE) One of the Best Healthcare Stocks to Buy Under $50?June 25, 2024 | globenewswire.comCEREVEL (NASDAQ:CERE) STOCK ALERT: Cerevel's $45 Per Share Deal is Being Investigated by BFA Law, Shareholders are Urged to Contact the FirmSee More Headlines Receive CERE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today8/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryCoal & Consumable Fuels Current SymbolNASDAQ:CERE CUSIP15677310 CIK767884 Webceres.net Phone844-304-2048FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Stock Price Target$44.13 High Stock Price Target$45.00 Low Stock Price Target$38.00 Potential Upside/Downside-1.9%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-432,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-98.94% Return on Assets-45.07% Debt Debt-to-Equity Ratio0.60 Current Ratio10.22 Quick Ratio10.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.71 per share Price / Book12.12Miscellaneous Outstanding Shares182,200,000Free Float172,903,000Market Cap$8.19 billion OptionableOptionable Beta1.40 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. N. Anthony Coles Jr. (Age 64)M.P.H., Executive Chairman Comp: $1.14MMr. Mark Bodenrader (Age 51)VP of Finance & Chief Accounting Officer Comp: $496.17kDr. John J. Renger Ph.D. (Age 55)Chief Scientific Officer Comp: $779.75kDr. Ramiro Sanchez M.D. (Age 63)Chief Medical Officer Comp: $805.13kMr. Ronald C. Renaud Jr. (Age 55)M.B.A., President, CEO & Director Dr. Susan Altschuller M.B.A. (Age 42)Ph.D., Chief Financial Officer Mr. Matthew CalistriVice President of Investor RelationsMr. Scott M. Akamine J.D. (Age 39)Chief Legal Officer & Corporate Secretary Comp: $444.74kMr. Kenneth A. DiPietro (Age 65)Chief Human Resources Officer Ms. Kathleen Tregoning M.A. (Age 53)Chief Corporate Affairs Officer Comp: $600.79kMore ExecutivesKey CompetitorsCNX ResourcesNYSE:CNXWarrior Met CoalNYSE:HCCArch ResourcesNYSE:ARCHHallador EnergyNASDAQ:HNRGTeva Pharmaceutical IndustriesNYSE:TEVAView All CompetitorsInsiders & InstitutionsWater Island Capital LLCSold 21,937 shares on 8/16/2024Ownership: 0.421%Susquehanna International Group LLPBought 215,800 shares on 8/16/2024Ownership: 0.000%Murchinson Ltd.Bought 100,000 shares on 8/16/2024Ownership: 0.055%Algert Global LLCBought 7,312 shares on 8/16/2024Ownership: 0.022%Dark Forest Capital Management LPSold 21,077 shares on 8/15/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions CERE Stock Analysis - Frequently Asked Questions How have CERE shares performed this year? Cerevel Therapeutics' stock was trading at $42.40 on January 1st, 2024. Since then, CERE shares have increased by 6.0% and is now trading at $44.96. View the best growth stocks for 2024 here. How were Cerevel Therapeutics' earnings last quarter? Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) released its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.02. Who are Cerevel Therapeutics' major shareholders? Top institutional investors of Cerevel Therapeutics include Avoro Capital Advisors LLC (4.14%), Alpine Associates Management Inc. (1.29%), Marshall Wace LLP (1.03%) and Farallon Capital Management LLC (0.65%). Insiders that own company stock include Bain Capital Investors Llc, Perceptive Advisors Llc, Ronald C Renaud Jr, N Anthony Coles, Kenneth Dipietro, Paul D Burgess, Mark Bodenrader, Susan Altschuller, Ramiro Sanchez, John Renger, Scott Akamine, Abraham Ceesay and Deval L Patrick. View institutional ownership trends. How do I buy shares of Cerevel Therapeutics? Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cerevel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO) and Hess (HES). This page (NASDAQ:CERE) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerevel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CERE Stock Alerts